Total Payments
$76,876
2022 Payments
$5,541
Companies
17
Transactions
81
Medicare Patients
1,833
Medicare Billing
$287,628
Payment Breakdown by Category
Other$64,160 (83.5%)
Consulting$7,528 (9.8%)
Food & Beverage$3,296 (4.3%)
Travel$1,893 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,160 | 19 | 83.5% |
| Consulting Fee | $7,528 | 11 | 9.8% |
| Food and Beverage | $3,296 | 40 | 4.3% |
| Travel and Lodging | $1,893 | 11 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41,867 | 31 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $23,466 | 21 | $0 (2020) |
| Genentech USA, Inc. | $5,039 | 5 | $0 (2017) |
| Celgene Corporation | $4,928 | 3 | $0 (2022) |
| AbbVie, Inc. | $234.56 | 2 | $0 (2019) |
| Varian Medical Systems, Inc. | $215.08 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $209.19 | 5 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $186.41 | 2 | $0 (2018) |
| Elekta, Inc. | $121.65 | 1 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $119.15 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $5,541 | 6 | Celgene Corporation ($4,928) |
| 2020 | $16,603 | 11 | Merck Sharp & Dohme Corporation ($10,052) |
| 2019 | $15,898 | 14 | E.R. Squibb & Sons, L.L.C. ($15,334) |
| 2018 | $8,443 | 20 | Merck Sharp & Dohme Corporation ($6,537) |
| 2017 | $30,391 | 30 | E.R. Squibb & Sons, L.L.C. ($18,382) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2022 | PFIZER INC. | XALKORI (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 05/10/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 05/05/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 04/12/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,927.50 | General |
| 04/12/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 04/20/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 03/24/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 03/23/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
| 03/18/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $101.22 | General |
| Category: Oncology | ||||||
| 02/28/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $87.64 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,140.00 | General |
| Category: Oncology | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $109.48 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 12/04/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,505.00 | General |
| Category: Oncology | ||||||
| 12/04/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $124.98 | General |
| Category: Oncology | ||||||
| 11/18/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $110.02 | General |
| Category: Oncology | ||||||
| 11/13/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,140.00 | General |
| Category: Oncology | ||||||
| 10/15/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 10/08/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 10/03/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $108.81 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 475 | 977 | $253,595 | $78,621 |
| 2022 | 10 | 459 | 923 | $233,404 | $78,589 |
| 2021 | 8 | 413 | 860 | $207,090 | $71,412 |
| 2020 | 11 | 486 | 865 | $188,048 | $59,006 |
Total Patients
1,833
Total Services
3,625
Medicare Billing
$287,628
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 93 | 260 | $95,508 | $29,066 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 128 | 303 | $78,477 | $22,152 | 28.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 98 | $24,304 | $9,270 | 38.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 87 | $14,616 | $5,682 | 38.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $13,485 | $4,116 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 64 | $11,392 | $2,925 | 25.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 43 | $5,203 | $1,812 | 34.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,280 | $1,681 | 31.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 13 | $3,900 | $1,395 | 35.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 27 | 65 | $1,430 | $521.63 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 88 | 235 | $78,020 | $27,859 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 134 | 317 | $74,495 | $24,260 | 32.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 69 | $16,629 | $5,901 | 35.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 49 | 98 | $16,464 | $5,851 | 35.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $14,880 | $4,555 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 69 | $11,109 | $3,047 | 27.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $6,118 | $2,280 | 37.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 23 | 65 | $7,865 | $2,083 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $4,224 | $1,386 | 32.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 12 | $3,600 | $1,367 | 38.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 134 | 321 | $71,981 | $24,562 | 34.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 81 | 209 | $66,044 | $24,467 | 37.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 37 | 37 | $16,576 | $5,424 | 32.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 61 | $14,701 | $5,347 | 36.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 96 | $16,128 | $5,190 | 32.2% |
About Dr. Jon Richards, M.D
Dr. Jon Richards, M.D is a Hematology & Oncology healthcare provider based in Park Ridge, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588624290.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jon Richards, M.D has received a total of $76,876 in payments from pharmaceutical and medical device companies, with $5,541 received in 2022. These payments were reported across 81 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($64,160).
As a Medicare-enrolled provider, Richards has provided services to 1,833 Medicare beneficiaries, totaling 3,625 services with total Medicare billing of $287,628. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Park Ridge, IL
- Active Since 03/25/2006
- Last Updated 12/20/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1588624290
Products in Payments
- OPDIVO (Biological) $41,017
- KEYTRUDA (Biological) $23,357
- Zelboraf (Biological) $4,913
- TrueBeam (Device) $166.83
- Venclexta (Drug) $125.94
- TAFINLAR (Drug) $124.99
- Mosaiq (Device) $121.65
- LIBTAYO (Biological) $119.15
- Creon (Drug) $108.62
- Imbruvica (Drug) $100.81
- CALQUENCE (Drug) $96.33
- AKYNZEO (Drug) $95.70
- Vectibix (Biological) $92.38
- TAGRISSO (Drug) $90.08
- Rubraca (Drug) $86.91
- NINLARO (Drug) $85.72
- MEKINIST (Drug) $65.41
- Edge (Device) $48.25
- TECENTRIQ (Biological) $21.25
- Bavencio (Biological) $15.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Park Ridge
Mrs. Sigrun Hallmeyer, Md, MD
Hematology & Oncology — Payments: $200,542
Hematology & Oncology $200,542
Dr. Edward James, M.d.,, M.D.,
Hematology & Oncology — Payments: $50,533
Hematology & Oncology $50,533
Dr. Jason Macklis, M.d, M.D
Hematology & Oncology — Payments: $14,505
Hematology & Oncology $14,505
Mrs. Pamela Kaiser, M.d, M.D
Hematology & Oncology — Payments: $13,644
Hematology & Oncology $13,644
Mr. Jacob Bitran, M.d, M.D
Hematology & Oncology — Payments: $5,156
Hematology & Oncology $5,156
Angel Galvez, M.d, M.D
Hematology & Oncology — Payments: $4,513
Hematology & Oncology $4,513